Proton pump inhibitors (PPIs), the most commonly used antisecretory medi-cations in the
management of reflux illness, virtually eliminate elective surgery for ulcer disease, and …

Aims Nocturnal acid breakthrough has been considered an unmet need of proton‐pump
inhibitors. Tegoprazan, a novel potassium‐competitive acid blocker, is expected to show …

Methods A randomized, double-blind, controlled, multicenter study was performed to
evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to …

BACKGROUND Fexuprazan, a novel potassium-competitive acid blocker, reversibly
suppresses the K+/H+-ATPase enzyme in proton pumps within gastric parietal cells …

Potassium-competitive acid blockers (PCABs) such as vonoprazan represent a novel class
of acid suppressants that show tremendous promise to enhance care of acid peptic …

Introduction Patients with acid-related disorders (ARDs) of the upper digestive tract remain
highly prevalent and need to be continuously investigated to improve their management …

Abstract Background and Aim Potassium‐competitive acid blockers (P‐CABs) can be used
to eradicate Helicobacter pylori infection. We aimed to evaluate the impact of treatment …

A physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for
tegoprazan and its major metabolite M1 was developed to predict PK and PD profiles under …

요약 위식도 역류 질환은 위내용물의 역류로 인하여 불편한 증상이 발생하거나 합병증이
동반되는 질병으로 임상 양상과 검사 소견 및 치료 반응성 측면에서 다양한 임상 양상을 …

Methods: A total of 236 patients newly diagnosed with H. pylori were enrolled in this multi-
center, prospective, open-label, and randomized controlled study. Patients randomly …